Sight Sciences (SGHT) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
23 Apr, 2026Executive summary
The 2026 Annual Meeting will be held virtually on June 4, 2026, with shareholders able to vote online using a 16-digit control number.
Shareholders will vote on electing two Class II Directors and ratifying the appointment of Deloitte & Touche LLP as the independent auditor for 2026.
The Board recommends voting in favor of both proposals and has provided detailed instructions for voting by internet, phone, or mail.
The proxy statement includes forward-looking statements regarding business outcomes, governance, and compensation, subject to risks outlined in the 2025 Annual Report.
Voting matters and shareholder proposals
Proposal 1: Election of Gerhard Burbach and Staffan Encrantz as Class II Directors to serve until the 2029 Annual Meeting.
Proposal 2: Ratification of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Both proposals require a majority or plurality of votes cast, with abstentions and broker non-votes having no effect.
No other business is expected, but proxies may vote at their discretion if new matters arise.
Shareholder proposals for the 2027 meeting must be submitted by December 23, 2026.
Board of directors and corporate governance
The Board consists of seven members divided into three staggered classes, with a majority being independent under Nasdaq rules.
Board diversity is disclosed, with two of seven directors self-identifying with diversity characteristics.
The Board has adopted Corporate Governance Guidelines, a Code of Business Conduct and Ethics, and charters for four standing committees.
The Chairperson of the Board is independent, and the roles of Chairperson and CEO are separated.
The Nominating and Corporate Governance Committee considers diversity, experience, and independence in director nominations.
Latest events from Sight Sciences
- Q1 2026 revenue up 13%, net loss narrowed, and $55.4M litigation award granted.SGHT
Q1 20266 May 2026 - Driving growth with innovative interventional eyecare technologies and strong clinical outcomes.SGHT
Investor presentation6 May 2026 - Vote on director elections and auditor ratification at the June 2026 virtual annual meeting.SGHT
Proxy filing23 Apr 2026 - Interventional eye care adoption accelerates, fueled by innovation, reimbursement, and strategic growth.SGHT
25th Annual Needham Virtual Healthcare Conference21 Apr 2026 - Q4 revenue rose 7% with strong margins; 2026 guidance targets up to 14% growth.SGHT
Q4 20254 Mar 2026 - OMNI and TearCare drive innovation in eyecare, targeting large, underserved markets.SGHT
investor presentation4 Mar 2026 - Interventional eye care advances with robust clinical data, aiming for payer coverage and renewed growth.SGHT
Morgan Stanley 23rd Annual Global Healthcare Conference3 Feb 2026 - Q2 revenue up 11% sequentially, net loss narrowed, and 2024 guidance set at $81–83M.SGHT
Q2 20242 Feb 2026 - Double-digit Q2 growth, strong margins, and strategic price hikes set up for 2025 acceleration.SGHT
Morgan Stanley 22nd Annual Global Healthcare Conference22 Jan 2026